Transgene
Develops cancer immunotherapies using vaccines and oncolytic viruses.
TNG | PA
Overview
Corporate Details
- ISIN(s):
- FR0005175080
- LEI:
- 969500PDJW8N0FSGGK69
- Country:
- France
- Address:
- 400 BOULEVARD GONTHIER D'ANDERNACH, 67400 ILLKIRCH-GRAFFENSTADEN
- Website:
- https://www.transgene.fr/en/
Description
Transgene is a clinical-stage biotechnology company that designs and develops immunotherapies for the treatment of cancer. The company's strategy is based on two proprietary technology platforms. The myvac® platform is used to create individualized neoantigen therapeutic vaccines, such as its clinical candidate TG4050, which leverages advanced genetic engineering and artificial intelligence. The invir.IO® platform is dedicated to developing innovative, multifunctional oncolytic viruses engineered to directly destroy cancer cells and modulate the tumor microenvironment, thereby enhancing the patient's immune response against the tumor.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-01-21 17:45 |
Transgene to Participate in the Biomed Forum Investor Conference
|
English | 248.1 KB | ||
| 2025-01-14 17:45 |
Transgene Announces Financial Calendar for 2025
|
English | 247.0 KB | ||
| 2025-01-14 17:45 |
Transgene présente son calendrier de communication financière pour 2025
|
French | 247.3 KB | ||
| 2025-01-07 18:00 |
Bilan du Contrat de Liquidité avec la Société Natixis Oddo BHF SCA au 31 décemb…
|
French | 167.8 KB | ||
| 2025-01-07 18:00 |
Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of Decembe…
|
English | 176.4 KB | ||
| 2024-11-07 17:45 |
Transgene et NEC présentent de nouvelles données confirmant la preuve de princi…
|
French | 453.1 KB | ||
| 2024-11-07 17:45 |
Transgene and NEC Present New Data Confirming Clinical Proof of Principle for N…
|
English | 464.1 KB | ||
| 2024-11-05 07:30 |
Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine De…
|
English | 375.7 KB | ||
| 2024-11-05 07:30 |
Transgene et ProBioGen collaborent pour faire progresser le développement des v…
|
French | 373.7 KB | ||
| 2024-10-14 07:30 |
Transgene fait le point sur l’étude de Phase II du vaccin thérapeutique TG4001 …
|
French | 388.1 KB | ||
| 2024-10-14 07:30 |
Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG400…
|
English | 2.2 MB | ||
| 2024-10-07 08:00 |
Transgene présentera un poster sur les données actualisées de TG4050 au SITC 20…
|
French | 277.5 KB | ||
| 2024-10-07 08:00 |
Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024
|
English | 380.2 KB | ||
| 2024-09-24 17:45 |
Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Fina…
|
English | 380.3 KB | ||
| 2024-09-24 17:45 |
Mise à disposition du Rapport Financier Semestriel au 30 juin 2024
|
French | 171.3 KB |
Automate Your Workflow. Get a real-time feed of all Transgene filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Transgene
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Transgene via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-30 | N/A | Other | Other | 30,898,876 | 32,999,999.57 EUR |
| 2023-05-26 | N/A | Other | Buy | 29,325 | N/A |
Peer Companies
